Healthcare industry has been doing researches and introducing various medications, treatments and drugs and have worked on a large scale in making positive differences for the better quality of life but there are still some areas where healthcare industries lack and have not been successful in finding cures and they are putting their maximum efforts. Such areas that are under consideration are pulmonary medicine, asthma treatment, COPD (chronic obstructive pulmonary disease) treatment and idiopathic pulmonary fibrosis.
The reason for these weak areas is because of the poor understanding of the COPD for a number of years. With the advancement in microbiology and general pathways of information, physicians know more about the disease that allow them to be better equipped to treat the disease at its roots cause. But at these points COPD and asthma are a bit unsatisfying to treat.
Struggling to control symptoms:
Physicians are working on symptom control and therapies for asthma and COPD. They are working to control the symptoms rather than getting to the roots of the problem and are dealing with the underlying cause of inflammatory process which leads to the long term conclusion.
In recent days there are bunch of physicians called as COPDs working on COPD but in future they going to end up with sub categories as the recent disease is actually a group of three to four diseases cause by different mechanism leading toward different therapies for each of the disease.
COPD includes asthma, emphysema, chronic bronchitis, bronchiectasis and cystic fibrosis. These all cause COPD that simply means chronic obstructive pulmonary disease. Each disorder has its own different positive mechanism that allows targeting these mechanisms.
Alpha 1-antitrypsin deficiency is simply a disorder which looks like COPD, acts like COPD and is treated like COPD with the exception of additional medication which is provided to the patient who actually treats the underlying cause of underlying alpha 1-antitrypsin deficiency. If the patients don’t have that genetic mutation that cause that cause alpha 1-antitrypsin deficiency, that treatment will not do anything for their COPD when it’s simply caused by smoking.
With the advancements in healthcare, physicians have found new drugs and new combination of different of inhalers which allow them to consolidate treatment for patients.
In trilogy study with GSK, physicians have introduced triple therapy for the patients and it’s helpful in treatment for the symptoms that COPD patients have. These treatments are available for the patient with different treatment plans and schedules.
Researchers are working on active areas of asthma and COPD to find therapy and the drugs for the disease that can allow them to treat their patients in completely different ways. There are multiple drugs under investigation and studies under procedures. All the asthmatics are now under lab testing to get CBC, IGE and rest testing to measure the improvements in their conditions.
Under the roofs of IACT Health, it provides a great practice and research culture to the physicians as well as for the patients and the patients always ready to participate and volunteer for the trials.